Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of melflufen plus dexamethasone in pomalidomide- and/or daratumumab-refractory multiple myeloma
2016-000965-21Phase 2Terminated
- Sponsor
- Oncopeptides AB
- Start
- Aug 2016
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of melphalan flufenamide in multiple myeloma (MM) (2 cohorts), sponsored by Oncopeptides AB. Primary endpoint: Overall response rate (ORR). Started Aug 2016; status: terminated.
02
Drugs
melphalan flufenamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2016-000965-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000965-21.